Amrita Sarkar

Amrita Sarkar

Auto-generated profile, based on publicly available information

Amrita Sarkar

Institute for Drug Research School of Pharmacy The Hebrew University of Jerusalem Jerusalem 9112102 Israel

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2020 in Inorganic Chemistry
Verified
Journal Article
Closed access
TBTomer Babu
Tomer Babu
ASAmrita Sarkar
Amrita Sarkar
SKSubhendu Karmakar
Subhendu Karmakar
CSClaudia Schmidt
Claudia Schmidt
DGDan Gibson
Dan Gibson

12 September 2023 in Angewandte Chemie International Edition
Verified
Journal Article
Open access
ASAmrita Sarkar
Amrita Sarkar
VNVojtech Novohradsky
Vojtech Novohradsky
MMMoumita Maji
Moumita Maji
TBTomer Babu
Tomer Babu
LMLenka Markova
Lenka Markova
DGDan Gibson
Dan Gibson
A multitargeting prodrug (2) that releases gemcitabine, oxaliplatin, and doxorubicin in their active form in cancer cells is a potent cytotoxic agent with nM IC50s; it is highly selective to cancer cells with mean selectivity indices to human (136) and murine (320) cancer cells. It effectively induces release of DAMPs (CALR, ATP & HMGB1) in CT26 cells facilitating more efficient phagocytosis by J774 macrophages than the FDA drugs or their co‐administration. The viability of CT26 cells co‐cultured with J774 macrophages and treated with 2 was reduced by 32 % compared to the non‐treated cells, suggesting a synergistic antiproliferative effect between the chemical and immune reactions. 2 inhibited in vivo tumor growth in two murine models (LLC and CT26) better than the FDA drugs or their co‐administration with significantly lower body weight loss. Mice inoculated with CT26 cells treated with 2 showed slightly better tumor free survival than doxorubicin.

2 January 2019 in Dalton Transactions
Verified
Journal Article
Closed access
PDF file
ASAmrita Sarkar
Amrita Sarkar
SASourav Acharya
Sourav Acharya
KKKumar Khushvant
Kumar Khushvant
KPKallol Purkait
Kallol Purkait
AMArindam Mukherjee
Arindam Mukherjee
Iodo coordinated half-sandwich RuII-anthraimidazoldione shows stability and low cytotoxicity even under hypoxia in metastatic cancer MDA-MB-231 cells (1–2 μM), induces apoptosis without ROS, and prevents migration at IC20dose.

11 September 2023 in Angewandte Chemie
Verified
Journal Article
Open access
ASAmrita Sarkar
Amrita Sarkar
VNVojtech Novohradsky
Vojtech Novohradsky
MMMoumita Maji
Moumita Maji
TBTomer Babu
Tomer Babu
LMLenka Markova
Lenka Markova
DGDan Gibson
Dan Gibson
A multitargeting prodrug (2) that releases gemcitabine, oxaliplatin, and doxorubicin in their active form in cancer cells is a potent cytotoxic agent with nM IC50s; it is highly selective to cancer cells with mean selectivity indices to human (136) and murine (320) cancer cells. It effectively induces release of DAMPs (CALR, ATP & HMGB1) in CT26 cells facilitating more efficient phagocytosis by J774 macrophages than the FDA drugs or their co‐administration. The viability of CT26 cells co‐cultured with J774 macrophages and treated with 2 was reduced by 32 % compared to the non‐treated cells, suggesting a synergistic antiproliferative effect between the chemical and immune reactions. 2 inhibited in vivo tumor growth in two murine models (LLC and CT26) better than the FDA drugs or their co‐administration with significantly lower body weight loss. Mice inoculated with CT26 cells treated with 2 showed slightly better tumor free survival than doxorubicin.